The presence of Cervical Cancer Stem Cells (CCSCs) in cases of Cervical Cancer (CC) represents a small subpopulation of tumor cells with a high potential for resistance to conventional treatments. Therapeutic targeting of CCSCs has the potential to reduce resistance to conventional therapies but also limit the occurrence of distant metastasis and relapse.
The paper, “Cancer Stem Cells and Their Possible Implications in Cervical Cancer: A Short Review,” has been published in the International Journal of Molecular Sciences. Co-authors Riccardo Di Fiore, Ph.D., and Jean Calleja-Agius, MD, Ph.D. of the University of Malta worked with Antonio Giordano, MD, Ph.D., Director, and Founder of the Sbarro Health Research Organization (SHRO) and the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia. This paper is based upon work from the COST Action CA18117—European network for Gynaecological Rare Cancer research: From Concept to Cure (GYNOCARE), supported by COST (European Co-operation in Science and Technology). COST is a funding agency for research and innovation networks. All authors are action management committee members and/or form part of the working groups of the GYNOCARE COST Action.